CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Conditions:   Leukemia;   Lymphoma, Large B-Cell, Diffuse;   Leukemia, B-cell;   Lymphoma, B-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell Intervention:   Biological: CD19 CAR-T cells Sponsor:   Chongqing Precision Biotech Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

This article reviews, in a systematic, organ-based approach, the acute metabolic and mechanical emergencies encountered in the emergency department in patients with hematologic malignancies.
Source: Contemporary Diagnostic Radiology - Category: Radiology Tags: ARTICLE Source Type: research
Authors: Allegra A, Innao V, Allegra AG, Pulvirenti N, Pugliese M, Musolino C Abstract Protease inhibitors (PIs) inhibit HIV‑1 and HIV‑2 proteases, impeding virus replication and liberation of viral elements from infected cells. In human immunodeficiency virus (HIV) subjects receiving PI‑based treatment, an impressive decrease in the amount of HIV‑associated cancers, unconnected to viral burden or CD4 amount was observed. Research has reported that PIs have influence on cancer proliferation, spread, and survival as an effect on endoplasmic reticulum stress, proteasome, NF‑κB and Akt signalling....
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Publication date: Available online 6 March 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shuvadeep Ganguly, Deepam Pushpam, Agrima Mian, Anita Chopra, Ritu Gupta, Sameer Bakhshi
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: This preliminary investigation in Iran shows that the main EBV genotype into our region probably is genotype I (91.2%) which it is similar to others. We could not find any statistically significant association between the virus infection and viral load with any specific disease and patients' demographic data. . PMID: 32212795 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+  (1&ndas...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: With up to 8 years of follow-up, sustained responses and long-term tolerability of single-agent ibrutinib were observed with treatment of first-line or relapsed/refractory CLL/SLL, including high-risk CLL/SLL. PMID: 32209572 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
This retrospective study was focused on 96 patients with HL treated between 2005 and 2008, in order to evaluate the outcome and the long-term mobility. After a median follow-up of 12 years, 85 patients (88%) are alive in CR and 11 (14%) have died (2 of a second neoplasia, 1 of infection, 8 of the disease).. Three women became pregnant and each gave birth to a healthy child. The most prevalent chronic conditions at last follow-up were: a reduction in DLCO (40%), fatigue (31%), hypothyroidism (30%), infertility (16%). The presence of a second neoplasm was documented in 4% of patients three DLBCLs were diagnosed at a median o...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
CONCLUSION: The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145). PMID: 32189590 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
More News: Biotechnology | Chronic Leukemia | Leukemia | Lymphoma | Research